Exploration of Targeted Anti-tumor Therapy

Table 2. Kinase fusions with preserved kinase domain

Kinase domain	Fusion’s name	Rearrangement (GRCh38)	5’-partner’s function	3’-partner’s function
5’-partner	MAPK10::LOC107986215	Intrachromosomal [chr4:3.95Mb]; chr4:86064266:– chr4:81915358:–	Serine/threonine-protein kinase; Neuronal proliferation, differentiation, migration, and programmed cell death	Non-coding RNA
	STK38::CDC73	Interchromosomal [chr6--chr1]; chr6:3649671:– chr1:193135391:+	Serine/threonine-protein kinase, transferase; Cell cycle and apoptosis, negative regulator of MAP3K1/2 signaling	Tumor suppressor; Cell cycle, regulation of transcription, Wnt signaling pathway
	BCR::PKHD1	Interchromosomal [chr22--chr6]; chr22:23273774:+ chr6:51960026:–	Serine/threonine-protein kinase, transferase; Guanine-nucleotide releasing factor	Receptor; Adhesion, cell motility
	CDC42BPG::ATG2A	Intrachromosomal [chr11:0.05Mb]; chr11:64832428:– chr11:64906815:–	Serine/threonine-protein kinase, transferase; Cytoskeletal reorganization, cell invasion	Transporter; Autophagy, lipid transport
	GALK2::FGF7	Intrachromosomal [chr15:0.06Mb]; chr15:49328130:+ chr15:49483151:+	Kinase, transferase; Metabolic protein	Growth factor; Heparin-binding, embryonic development, cell proliferation, and differentiation
3’-partner	CLTC::RPS6KB1	Intrachromosomal [chr17:0.20Mb]; chr17:59677188:+ chr17:59910562:+	Transporter; Autophagy, cell cycle, cell division, mitosis	Serine/threonine-kinase, transferase; Apoptosis, cell cycle, and regulation of translation
	ATXN2L::SMG1	Intrachromosomal [chr16:9.90Mb]; chr16:28825402:+ chr16:18876393:–	Plasma protein; Neurodegenerative disorders	Serine/threonine-kinase; DNA damage, DNA repair, nonsense-mediated mRNA decay
	WASF2::FGR	Intrachromosomal [chr1:0.12Mb]; chr1:27414833:– chr1:27617296:–	Actin-binding protein; Changes in cell shape, motility, or function	Non-receptor tyrosine-kinase; Immunity

Return to article view

Chr: chromosome

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002330_sup_1.xlsx.

Declarations

Author contributions

EVP: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Writing—review & editing, Visualization. RSM, FAZ, ESS, PRK, JOB, and VIT: Investigation. AAR: Investigation, Formal analysis. IVB: Methodology, Formal analysis. ENI: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

Evgeny N. Imyanitov who is the Editorial Board Member of Exploration of Targeted Anti-tumor Therapy had no involvement in the decision-making or the review process of this manuscript. Other authors declare that they have no conflicts of interest.

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki 2013 and approved by the local Ethical Committee of N.N. Petrov Institute of Oncology (Approval Code: 753. Approval Date: 31 October 2023).

Consent to participate

Informed consent was obtained from all subjects involved in the study.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This research has been supported by the Russian Science Foundation, grant number [24-45-10014]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, et al. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene. 2013;32:27–38. [DOI] [PubMed]

Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel). 2021;13:2748. [DOI] [PubMed] [PMC]

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54. [DOI] [PubMed]

Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023;20:229–49. [DOI] [PubMed] [PMC]

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023;7:101. [DOI] [PubMed] [PMC]

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18:35–55. [DOI] [PubMed] [PMC]

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47. [DOI] [PubMed] [PMC]

Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer. 2020;140:46–54. [DOI] [PubMed]

Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al.; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:944–57. [DOI] [PubMed]

10.

Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, Granata B, Lazzari C, et al. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? Int J Mol Sci. 2023;24:10119. [DOI] [PubMed] [PMC]

11.

Nützinger J, Bum Lee J, Li Low J, Ling Chia P, Talisa Wijaya S, Chul Cho B, et al. Management of HER2 alterations in non-small cell lung cancer—The past, present, and future. Lung Cancer. 2023;186:107385. [DOI] [PubMed]

12.

Imyanitov EN, Preobrazhenskaya EV, Orlov SV. Current status of molecular diagnostics for lung cancer. Explor Target Antitumor Ther. 2024;5:742–65. [DOI] [PubMed] [PMC]

13.

Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213. [DOI] [PubMed] [PMC]

14.

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9. [DOI] [PubMed] [PMC]

15.

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. [DOI] [PubMed] [PMC]

16.

Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, et al. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021;600:319–23. [DOI] [PubMed] [PMC]

17.

Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121–6. [DOI] [PubMed] [PMC]

18.

Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, et al. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. JTO Clin Res Rep. 2022;3:100332. [DOI] [PubMed] [PMC]

19.

Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, et al. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clin Cancer Res. 2022;28:461–7. [DOI] [PubMed]

20.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019;25:64–72. [DOI] [PubMed]

21.

Cobleigh MA, Abukheir AM. Binimetinib activity in PIK3R1-mutant patient-derived xenografts (PDX) implanted into immunodeficient mice. J Clin Oncol. 2021;39:e13062. [DOI]

22.

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020;80:4986–97. [DOI] [PubMed]

23.

Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, et al.; BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23:248–58. [DOI] [PubMed]

24.

Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, et al. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget. 2017;8:46891–9. [DOI] [PubMed] [PMC]

25.

Blum AE, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, et al. RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res. 2016;76:5628–33. [DOI] [PubMed] [PMC]

26.

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. [DOI] [PubMed] [PMC]

27.

Zhu YC, Wang WX, Li XL, Xu CW, Chen G, Zhuang W, et al. Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. J Thorac Oncol. 2019;14:e181–3. [DOI] [PubMed]

28.

Wang W, Lv W, Wang H, Xu Y, Yan J, Shen H, et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma. Genes Dis. 2023;10:2241–4. [DOI] [PubMed] [PMC]

29.

Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024;42:258–65. [DOI] [PubMed] [PMC]

30.

Aleksakhina SN, Ivantsov AO, Imyanitov EN. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. Int J Mol Sci. 2024;25:4094. [DOI] [PubMed] [PMC]

31.

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–75. [DOI] [PubMed] [PMC]